Outpatient parenteral antimicrobial therapy for patients with
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
14
08
2024
accepted:
02
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Many patients with To assess the outcomes for adults with We retrospectively reviewed adults who received at least 2 weeks duration of OPAT for Forty-four patients met inclusion criteria. Fifteen were female (34%). The median age was 80 (IQR 71.5 to 84) years. Twenty-two (50%) had prosthetic valve (PV), 15 (34%) native valve (NV), 3 (7%) NV and/or cardiac implantable electronic device (CIED) infection, 3 (7%) PV and/or CIED infection, and 1 (2%) repaired valve endocarditis. Patients received a median of 16.5 days inpatient and 28 days OPAT antibiotic treatment. The 12 month outcome was cure ( This study adds to the accumulating evidence supporting the treatment of
Sections du résumé
Background
UNASSIGNED
Many patients with
Objectives
UNASSIGNED
To assess the outcomes for adults with
Patients and methods
UNASSIGNED
We retrospectively reviewed adults who received at least 2 weeks duration of OPAT for
Results
UNASSIGNED
Forty-four patients met inclusion criteria. Fifteen were female (34%). The median age was 80 (IQR 71.5 to 84) years. Twenty-two (50%) had prosthetic valve (PV), 15 (34%) native valve (NV), 3 (7%) NV and/or cardiac implantable electronic device (CIED) infection, 3 (7%) PV and/or CIED infection, and 1 (2%) repaired valve endocarditis. Patients received a median of 16.5 days inpatient and 28 days OPAT antibiotic treatment. The 12 month outcome was cure (
Conclusions
UNASSIGNED
This study adds to the accumulating evidence supporting the treatment of
Identifiants
pubmed: 39464856
doi: 10.1093/jacamr/dlae168
pii: dlae168
pmc: PMC11503647
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlae168Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.